Kainova Therapeutics, formerly known as Domain Therapeutics, is a clinical-stage biopharmaceutical company headquartered in Montreal, Quebec. The company drives a clinical pipeline of advanced GPCR-modulating therapies to address unmet medical needs.
Subscribe to see Kainova Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Kainova Therapeutics is a drug discovery company headquartered in Canada. Its most recent funding round, Series B, raised $23.6M in February 2026. Xcout tracks 3 named people at Kainova Therapeutics, including Sean A. MacDonald (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $23.6M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Kainova Therapeutics's closest competitors — see the full list of competitors and alternatives →
KayoThera, Inc. is an early-stage, preclinical therapeutics company headquartered in Seattle, Washington. The firm focuses on developing first-in-class, oral, small molecule treatments.
Vima Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The firm pioneers treatments for dystonia and related movement disorders, focusing on novel oral therapies. It develops specialized therapeutics designed to help patients regain mobility and freedom of movement.
Kinoxis Therapeutics Pty Ltd is an Australian-based, clinical-stage biotechnology company that develops first-in-class therapeutics targeting ALOX15 to address central nervous system (CNS) diseases.
Neurasic Therapeutics is a Montreal-based drug discovery company founded in 2020 and based on research from McGill University's Montreal Neurological Institute. The company develops therapeutic solutions and medicinal drugs aimed at treating neurological disorders, with a primary focus on advancing opiate-sparing, pain-relieving treatments such as substituted thiophene for neuropathic and inflammatory pain.
Pangea Bio is a clinical-stage biotechnology research company headquartered in London focused on central nervous system (CNS) drug discovery.
Variational AI is a privately held biotechnology startup headquartered in Vancouver, British Columbia. Founded in 2019, the company focuses on drug discovery, utilizing artificial intelligence to identify novel drug-like small molecules. Recognized as an innovative AI enterprise in Canada, it develops advanced computational methods for pharmaceutical research.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Kainova Therapeutics? Suggest a correction · Work at Kainova Therapeutics? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.